Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 1, 2016, Pages 334-342

  Whyte, Michael P ^a,b   Rockman Greenberg, Cheryl ^c   Ozono, Keiichi ^d   Riese, Richard ^e   Moseley, Scott ^e   Melian, Agustin ^e   Thompson, David D ^e   Bishop, Nicholas ^f,g   Hofmann, Christine ^h  

^a SHRINERS HOSPITAL FOR CHILDREN   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d OSAKA UNIVERSITY   (Japan)

^e ALEXION PHARMACEUTICALS   (United States)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^h UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASFOTASE ALFA; ALKALINE PHOSPHATASE; HYBRID PROTEIN; IMMUNOGLOBULIN G;

ARTICLE; ARTIFICIAL VENTILATION; BONE MINERALIZATION; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HYPOPHOSPHATASIA; INFANT; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEWBORN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; AGE; BONE DENSITY; CLINICAL TRIAL; ENZYME REPLACEMENT; KAPLAN MEIER METHOD; LUNG FUNCTION TEST; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGE FACTORS; ALKALINE PHOSPHATASE; BONE DENSITY; CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; FEMALE; HUMANS; HYPOPHOSPHATASIA; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIER ESTIMATE; MALE; RECOMBINANT FUSION PROTEINS; RESPIRATION, ARTIFICIAL; RESPIRATORY FUNCTION TESTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84954547947     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3462     Document Type: Article

References (37)

1. Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012; 366:904-913.
2. Whyte MP. Hypophosphatasia. In: Thakker RV, Whyte MP, Eisman JA, Igarashi T, eds. Genetics of Bone Biology and Skeletal Disease. Amsterdam, The Netherlands: Elsevier/Academic Press; 2013:337-360.
3. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 1966;212:901-903.
4. Weiss MJ, Cole DE, Ray K, et al. A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a form of lethal hypophosphatasia. Proc Natl Acad Sci USA. 1988;85:7666-7669.
5. Hofmann C, Girschick H, Mornet E, Schneider D, Jakob F, Mentrup B. Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia. Eur J Hum Genet. 2014;22:1160-1164.
6. Mornet E, Beck C, Bloch-Zupan A, Girschick H, Le Merrer M. Clinical utility gene card for: Hypophosphatasia. Eur J Hum Genet. 2011;19:(3).
7. Mornet E. The Tissue Nonspecific Alkaline Phosphatase Gene Mutations Database. http://www.sesep.uvsq.fr/03-hypo-mutations. php. Accessed September 9, 2105.
8. Fraser D. Hypophosphatasia. Am J Med. 1957;22:730-746.
9. Whyte MP, Zhang F, Wenkert D, et al. Hypophosphatasia: Validation and expansion of the clinical nosology for children from 25 years' experience with 173 pediatric patients. Bone. 2015;75:229-239.
10. Baumgartner-Sigl S, Haberlandt E, Mumm S, et al. Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T-C, p.M226T; c.1112C-T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone. 2007;40:1655-1661.
11. Leung EC, Mhanni AA, Reed M, Whyte MP, Landy H, Greenberg CR. Outcome of perinatal hypophosphatasia in Manitoba Mennonites: A retrospective cohort analysis. JIMD Rep. 2013;11:73-78.
12. Silver MM, Vilo GA, Milne KJ. Pulmonary hypoplasia in neonatal hypophosphatasia. Pediatr Pathol. 1988;8:483-493.
13. Whyte MP. Hypophosphatasia. In: Glorieux FH, Pettifor JM, Juppner H, eds. Pediatric Bone: Biology and Diseases. London, UK: Academic Press; 2012:771-794.
14. Rodriguez E, BoberMB,Davey L, et al. Respiratory mechanics in an infant with perinatal lethal hypophosphatasia treated with human recombinant enzyme replacement therapy. Pediatr Pulmonol. 2012; 47:917-922.
15. Millán JL, Plotkin H. Hypophosphatasia-pathophysiology and treatment. Actual Osteol. 2012;8:164-182.
16. Litmanovitz I, Reish O, Dolfin T, et al. Glu274Lys/Gly309Arg mutation of the tissue-nonspecific alkaline phosphatase gene in neonatal hypophosphatasia associated with convulsions. J Inherit Metab Dis. 2002;25:35-40.
17. Nunes ML, Mugnol F, Bica I, Fiori RM. Pyridoxine-dependent seizures associated with hypophosphatasia in a newborn. J Child Neurol. 2002;17:222-224.
18. Deeb AA, Bruce SN, Morris AA, Cheetham TD. Infantile hypophosphatasia: Disappointing results of treatment. Acta Paediatr. 2000; 89:730-733.
19. Wenkert D, McAlister WH, Coburn SP, et al. Hypophosphatasia: Nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). J Bone Miner Res. 2011;26:2389-2398.
20. Taketani T, Onigata K, Kobayashi H, Mushimoto Y, Fukuda S, Yamaguchi S. Clinical and genetic aspects of hypophosphatasia in Japanese patients. Arch Dis Child. 2014;99:211-215.
21. Thacher TD, Fischer PR, Pettifor JM, Lawson JO, Manaster BJ, Reading JC. Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr. 2000;46:132-139.
22. Girschick HJ, Mornet E, Beer M, Warmuth-Metz M, Schneider P. Chronic multifocal non-bacterial osteomyelitis in hypophosphatasia mimicking malignancy. BMC Pediatr. 2007;7:3.
23. Girschick HJ, Schneider P, Kruse K, Huppertz HI. Bone metabolism and bone mineral density in childhood hypophosphatasia. Bone. 1999;25:361-367.
24. Gorodischer R, Davidson RG, Mosovich LL, Yaffe SJ. Hypophosphatasia: A developmental anomaly of alkaline phosphatase? Pediatr Res. 1976;10:650-656.
25. Beisel WR, Benjamin N, Austen KF. Absence of leukocyte alkaline phosphatase activity in hypophosphatasia. Blood. 1959;14:975-977.
26. Seshia SS, Derbyshire G, Haworth JC, Hoogstraten J. Myopathy with hypophosphatasia. Arch Dis Child. 1990;65:130-131.
27. Collmann H, Mornet E, Gattenlöhner S, Beck C, Girschick H. Neurosurgical aspects of childhood hypophosphatasia. Childs Nerv Syst. 2009;25:217-223.
28. Deneke SM, Fanburg BL. Normobaric oxygen toxicity of the lung. N Engl J Med. 1980;303:76-86.
29. Davis WB, Rennard SI, Bitterman PB, Crystal RG. Pulmonary oxygen toxicity. Early reversible changes in human alveolar structures induced by hyperoxia. N Engl J Med. 1983;309:878-883.
30. Couser RJ, Ferrara TB, Ebert J, Hoekstra RE, Fangman JJ. Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease. J Pediatr. 1990;116:119-124.
31. Gortner L, Bartmann P, Pohlandt F, et al. Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: A multicenter controlled clinical trial. Pediatr Pulmonol. 1992;14:4-9.
32. The HIFI Group. High frequency oscillatory ventilation compared with conventional mechanical ventilation in the treatment of respiratory failure in preterm infants. N Engl J Med. 1989;320:88-93.
33. Barrington KJ, Bull D, Finer NN. Randomized trial of nasal synchronized intermittent mandatory ventilation compared with continuous positive airway pressure after extubation of very low birth weight infants. Pediatrics. 2001;107:638-641.
34. Khalaf MN, Brodsky N, Hurley J, Bhandari V. A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation versus positive airway pressure as modes of extubation. Pediatrics. 2001;108:13-17.
35. Greenberg CR, Taylor CL, Haworth JC, et al. A homoallelic Gly317-Asp mutation in ALPL causes the perinatal (lethal) form of hypophosphatasia in Canadian Mennonites. Genomics. 1993; 17:215-217.
36. Ozono K, Yamagata M, Michigami T, et al. Identification of novel missense mutations (Phe310Leu and Gly439Arg) in a neonatal case of hypophosphatasia. J Clin Endocrinol Metab. 1996;81:4458-4561.
37. Michigami T, Uchihashi T, Suzuki A, Tachikawa K, Nakajima S, Ozono K. Common mutations F310L and T1559del in the tissuenonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia. Eur J Pediatr. 2005;164:277-282.